BAO PHARMA-B's stock surged 5.80% during Tuesday's intraday session, driven by multiple positive catalysts that boosted investor sentiment.

The rally was primarily fueled by the company's recent inclusion in the MSCI Global Small Cap Index, with the adjustment set to take effect after the close on May 29. This inclusion is expected to attract incremental passive fund allocation, enhance market liquidity, and elevate the company's international visibility among global institutional investors.

Additional supportive factors include controlling shareholder Dr. Liu Yanjun's ongoing plan to acquire up to 38.8939 million H shares within three months, and the company's injectable KJ103 — a first-in-class recombinant IgG-degrading enzyme for desensitization therapy in highly sensitized kidney transplant patients — being proposed for priority review by the CDE. These developments have reinforced market confidence in the company's pipeline and long-term growth prospects.